查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1544599

僵直性脊椎炎市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Ankylosing Spondylitis Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 220 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於人們對僵直性脊椎炎的認知和診斷的提高，以及治療方案的進步，預計 2024 年至 2032 年間，僵直性脊椎炎的市場規模將以 8.2% 的複合年成長率成長。影像技術和生物標記發現的創新促進了更早、更精確的診斷，從而增加了對專業治療和管理策略的需求。

僵直性脊椎炎（AS）盛行率的上升和患者群體的擴大也推動了市場的成長。報告顯示，僵直性脊椎炎影響全球 0.1% 至 1.4% 的人口。隨著遺傳和環境因素導致 AS 發病率不斷增加，對有效治療解決方案和管理策略的需求不斷增加。此外，研發投資的增加以及新治療方法正在進行的臨床試驗正在促進創新藥物和治療方式的創造。

本行業分為治療、給藥途徑、類型、應用、配銷通路和地區。

根據治療，由於皮質類固醇在減輕發炎和控制僵直性脊椎炎相關症狀方面的功效已被證明，皮質類固醇領域的僵直性脊椎炎市場規模預計將在 2024 年至 2032 年間成長。皮質類固醇不僅可以迅速緩解疼痛和腫脹，提高患者的活動能力和整體生活品質，而且在控制急性發作和調節免疫反應方面發揮關鍵作用，從而顯著增加了他們的需求。

從 2024 年到 2032 年，青少年應用領域的 AS 市場預計將出現顯著的複合年成長率。患有早發性 AS 的青少年通常表現出獨特的臨床特徵，如果不及時干預，就會面臨更嚴重的後果。這一現實強調了對專門護理和量身定做的治療策略的需求，以滿足年輕患者的獨特需求。

亞太地區僵直性脊椎炎產業預計從 2024 年到 2032 年將出現顯著成長。先進診斷設備的激增，加上專門的治療中心，不僅有利於早期診斷，而且可以確保有效的管理，促進區域市場的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 僵直性脊椎炎盛行率增加
      • 治療方案的進步
      • 醫療保健支出增加
    • 產業陷阱與挑戰
      • 與藥物相關的副作用
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按處理方式，2021 - 2032 年

  • 主要趨勢
  • 非類固醇類抗發炎藥（NSAID）
  • 生物療法
    • 腫瘤壞死因子抑制劑
    • IL-17抑制劑
  • JAK抑制劑
  • 緩解病情抗風濕藥物 (DMARD)
  • 皮質類固醇

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

  • 主要趨勢
  • 注射用
  • 口服

第 7 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 處方藥
  • 非處方藥

第 8 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 成年人
  • 少年

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 11 章：公司簡介

  • AbbVie, Inc.
  • Amgen, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Horizon Pharma
  • Janssen Biotech, Inc.
  • Merck and Co., Inc.
  • Novartis AG
  • PRIMUS PHARMACEUTICALS
  • Pfizer, Inc.
  • Sandoz Group AG
  • UCB, Inc.
簡介目錄
Product Code: 10134

Ankylosing spondylitis market size is anticipated to grow at an 8.2% CAGR between 2024 and 2032 driven by increasing awareness and diagnosis of the condition, coupled with advancements in treatment options. Innovations in imaging technologies and biomarker discoveries have facilitated earlier and more precise diagnoses, subsequently boosting the demand for specialized treatments and management strategies.

The market growth is also propelled by the rising prevalence of ankylosing spondylitis (AS) and an expanding patient demographic. Reports indicate that ankylosing spondylitis affects between 0.1% to 1.4% of the global population. As genetic and environmental factors drive the increasing incidence of AS, the demand for effective treatment solutions and management strategies intensifies. Moreover, heightened investments in R and D, alongside ongoing clinical trials for new therapeutic methods, are catalyzing the creation of innovative drugs and treatment modalities.

The industry is classified into treatment, route of administration, type, application, distribution channel, and region.

Based on treatment, the ankylosing spondylitis market size from the corticosteroids segment is poised to grow between 2024 and 2032 due to their proven efficacy in alleviating inflammation and managing AS-related symptoms. Corticosteroids not only offer swift relief from pain and swelling, enhancing patient mobility and overall quality of life but also play a pivotal role in controlling acute flare-ups and modulating immune responses, significantly boosting their demand.

AS market from the juvenile application segment is set to witness a significant CAGR from 2024 to 2032. This is driven by the rising acknowledgment and diagnosis of the disease in younger demographics, notably children and adolescents. Juveniles with early-onset AS often exhibit unique clinical features and face graver outcomes without timely intervention. This reality underscores the demand for specialized care and tailored treatment strategies that cater to the distinct needs of younger patients.

Asia Pacific ankylosing spondylitis industry is expected to accrue notable growth from 2024 to 2032. The growth is attributed to enhancements in healthcare infrastructure and a growing awareness of inflammatory diseases. The proliferation of advanced diagnostic facilities, coupled with specialized treatment centers, not only facilitates early diagnosis but also ensures effective management, bolstering the regional market expansion.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of ankylosing spondylitis
      • 3.2.1.2 Advancements in treatment options
      • 3.2.1.3 Rising healthcare expenditure
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Side effects associated with the medications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Non-steroidal anti-inflammatory drugs (NSAIDs)
  • 5.3 Biologic therapies
    • 5.3.1 TNF inhibitors
    • 5.3.2 IL-17 inhibitors
  • 5.4 JAK Inhibitors
  • 5.5 Disease-modifying anti-rheumatic drugs (DMARDs)
  • 5.6 Corticosteroids

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Parenteral
  • 6.3 Oral

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Prescription drugs
  • 7.3 OTC drugs

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Adults
  • 8.3 Juveniles

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 AbbVie, Inc.
  • 11.2 Amgen, Inc.
  • 11.3 Bayer AG
  • 11.4 Eli Lilly and Company
  • 11.5 Horizon Pharma
  • 11.6 Janssen Biotech, Inc.
  • 11.7 Merck and Co., Inc.
  • 11.8 Novartis AG
  • 11.9 PRIMUS PHARMACEUTICALS
  • 11.10 Pfizer, Inc.
  • 11.11 Sandoz Group AG
  • 11.12 UCB, Inc.